Equites Radar

IDXX · IDEXX Laboratories, Inc.

Diagnostics & ResearchUnited StatesAnalyst view: Buy

$556.20

+2.40% last session

End-of-day data · updated 2026-07-29

Mildly bearish2 bullish · 3 bearish technical signals
Consensus: Buy (2.13 from 14 analysts)
To mean target: +27.1%

Market cap

$45B

Enterprise value

$46B

Trailing P/E

42.0

Forward P/E

34.5

Dividend yield

Beta

1.55

Avg volume

1M

Employees

11K

2D change

2.40%

5D change

10D change

0.37%

30D change

6.27%

60D change

1.07%

MTD change

5.95%

YTD change

-15.81%

Analyst Outlook

Consensus ratingBuy
Recommendation mean (1–5)2.13
Covering analysts14
Mean price target$707.00
Low price target$470.00
Upside to mean target+27.1%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)54.8
50-day MA$555.54
200-day MA$621.89
Price vs 50-day MA+2.5%
Price vs 200-day MA-8.4%
MACD histogram0.23
Volume vs 3-month avg0.7×
52w low $526.4452w high $766.68

Analyst sentiment over time — IDXX

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-07-27

Latest call per bank · past 12 months

UBS

Neutral

$620

+11.5% vs price
▼ cut from $640Maintains · 2026-07-27

Citigroup

Neutral

$650

+16.9% vs price
▲ raised from $0.00Initiates · 2026-04-15

Barclays

Overweight

$800

+43.8% vs price
▼ cut from $850Maintains · 2026-02-05

Morgan Stanley

Overweight

$805

+44.7% vs price
▲ raised from $765Maintains · 2025-11-04

JP Morgan

Overweight

$775

+39.3% vs price
▲ raised from $675Maintains · 2025-11-04

Recent rating actions

DateFirmActionRatingPrice target
2026-07-27UBSMaintainsNeutral$640 $620
2026-04-28UBSMaintainsNeutral$730 $640
2026-04-15CitigroupInitiatesNeutral$0.00 $650
2026-03-31StifelMaintainsBuy$775 $675
2026-02-09Piper SandlerMaintainsNeutral$775 $750
2026-02-05BarclaysMaintainsOverweight$850 $800
2026-02-03UBSMaintainsNeutral$750 $730
2026-02-03BTIGMaintainsBuy$830 $800

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-07-28

  • RSI (14): RSI is 55 — neutral momentum, neither overbought nor oversold.
  • Price vs 50-day MA: Trading 2.5% above the 50-day MA ($555.54).
  • Price vs 200-day MA: Trading 8.4% below the 200-day MA ($621.89).
  • MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
  • MACD (12,26,9): MACD histogram is positive (+0.23) — short-term momentum is improving.
  • 52-week range: Price is within 10% of the 52-week low ($526.44).

IDXX Price Chart

Loading chart for IDXX

Fundamentals

Revenue (TTM)$4.0B
EBITDA$2.0B
Free cash flow$1.0B
Operating cash flow$1.0B
Book value / share$19.64
Net debt / EBITDA0.6
WACC14.0%
Revenue growth14.00%
Earnings growth17.00%

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

More in Diagnostics & Research

Screen IDXX against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.